Holzkirchen, Germany
Holzkirchen, Germany

Time filter

Source Type

News Article | May 23, 2017
Site: www.prnewswire.com

The global biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region. On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is estimated to account for the largest share of the biosimilars market, in 2016. Factors such as new product launches, cost-effectiveness, growing incidence of diabetes, and presence of many biosimilar versions of insulin in the pipeline are driving growth in this market. On the basis of manufacturing type, the market is segmented into in-house manufacturing and contract manufacturing organizations. The contract manufacturing organizations segment is projected to witness the highest CAGR during the forecast period. On the basis of application, the market is segmented into oncology, blood disorders, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other applications. In 2016, the oncology segment is expected to account for the largest share of the market. Geographically, the biosimilars market is dominated by Europe, followed by Asia, North America, and the Rest of the World (RoW). Growth in the European market is attributed to the growing pressure to curtail healthcare costs, patent expiry of biologics & the arrival of new biosimilars, and the rising incidence of chronic disorders. Apart from comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market. The key players in the biosimilars market include Pfizer Inc. (U.S.), Sandoz International GmbH (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Amgen Inc. (U.S.), Biocon Ltd. (India), Dr. Reddy's Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd. (Switzerland), Celltrion Inc. (South Korea), and Samsung Bioepis (South Korea). This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares. The report provides insights on the following pointers: - Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market. The report analyses the biosimilars market by product, manufacturing type, and application. - Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the biosimilars market - Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market - Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars products across geographies - Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biosimilars-market-is-expected-to-reach-usd-1090-billion-by-2021-300462189.html


News Article | November 17, 2016
Site: www.newsmaker.com.au

Growth hormone deficiency (GHD) is a medical condition characterized by insufficient production of somatropin, a growth hormone, from the anterior pituitary gland which is responsible for the growth and cell reproduction. Though the exact cause of growth hormone deficiency is obscure, it is considered to be of genetic origin or also it can develop after a trauma, brain injury, due to pituitary tumors etc. Children with growth hormone deficiency show retarded growth and sometimes delayed puberty. Symptoms of growth hormone deficiency vary among adults and children. The predominant symptom in children is that the child is abnormally shorter than other children of his age with or without compromise in the cognitive intelligence while in adults, growth hormone deficiency may lead to fatigue, tiredness, anxiety and depression. Growth hormone deficiency is treated with growth hormone injections on daily or weekly basis although the effects of therapy starts showing after 2-3 months of therapy. The primary factor contributing to the growth of global growth hormone deficiency treatment market is increasing incidence of growth hormone deficiency syndrome. Several other factors which may cause the global growth hormone deficiency market to grow include changing lifestyle, prevalence of other genetic disorders and incidence of GHD in adults. However, high cost of treatment will always remain the major restraint for global growth hormone deficiency treatment market. Surgeries in treatment of growth hormone deficiency treatment are rarely performed. Recombinant human growth hormone sub-segment of pharmacological therapy treatment type is expected to hold major share in the global growth hormone deficiency treatment market due to increased patient compliance. Home care settings’ end user segment occupies significant proportion of global growth hormone deficiency treatment market owing to the nature of a therapy requiring daily dosage administration. Introduction of new medicines such as Saizen solution is anticipated to expand the market growth of global growth hormone deficiency treatment market over the forecast period of 2016-2026. Geographically, the global growth hormone deficiency treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.  North America is expected to contribute largest market share in global growth hormone deficiency treatment market followed by Europe. Emerging markets such as China, India, and Brazil are expected to present good opportunity for growth hormone deficiency treatment market due to entrance of key players into the market. Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/9962 Some of the major players in the global growth hormone deficiency treatment market include Sandoz International GmbH, Sanofi Aventis, Pfizer, Novo Nordisk A/S, Teva Pharmaceutical Industries Limited, Ranbaxy, EMD Serono, Inc., Sun Pharmaceutical Industries Ltd., Eli Lilly and Company and others.


Receive press releases from iHealthcareAnalyst, Inc.: By Email Global Highly Potent Active Pharmaceutical Ingredients Market by APIs, Drugs, Manufacturing, Therapeutics and Forecast to 2020, New Research by iHealthcareAnalyst, Inc. Maryland Heights, MO, March 02, 2017 --( Browse Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic, OTC), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/ Highly potent active pharmaceutical ingredients (HPAPIs) represent a significant change in the way pharmaceutical innovators are using small molecules to deliver new patient therapies. The shift toward highly potent APIs has not only led to a pipeline of more effective medicines that require lower doses and lead to fewer side effects, but also to new manufacturing challenges. During the last decade, the demand for HPAPIs has grown rapidly, mainly as a result of advances in clinical pharmacology and oncology research. HPAPIs drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the U.S. FDA, EMEA and other international regulatory agencies. Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability, geographical advantage and cost-effectiveness. The global highly potent active pharmaceutical ingredients (HPAPIs) market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the API (biological, chemical), drug (branded, generic, OTC), manufacturing (in-house, outsourcing or contact-based), therapeutic area (diabetes, cardiovascular, CNS, oncology, musculoskeletal drugs, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global highly potent active pharmaceutical ingredients market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global highly potent active pharmaceutical ingredients market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global highly potent active pharmaceutical ingredients (HPAPIs) market and included in this report are Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC, and WuXi AppTec. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, March 02, 2017 --( PR.com )-- The global potent active pharmaceutical ingredients (HPAPIs) market to reach nearly USD 18.5 Billion in 2020, at a CAGR of 6.2% from 2016 to 2020, majorly due to patent expiry of blockbuster drugs and growing trend in pharmaceutical outsourcing.Browse Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic, OTC), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/Highly potent active pharmaceutical ingredients (HPAPIs) represent a significant change in the way pharmaceutical innovators are using small molecules to deliver new patient therapies. The shift toward highly potent APIs has not only led to a pipeline of more effective medicines that require lower doses and lead to fewer side effects, but also to new manufacturing challenges. During the last decade, the demand for HPAPIs has grown rapidly, mainly as a result of advances in clinical pharmacology and oncology research. HPAPIs drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the U.S. FDA, EMEA and other international regulatory agencies. Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability, geographical advantage and cost-effectiveness.The global highly potent active pharmaceutical ingredients (HPAPIs) market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the API (biological, chemical), drug (branded, generic, OTC), manufacturing (in-house, outsourcing or contact-based), therapeutic area (diabetes, cardiovascular, CNS, oncology, musculoskeletal drugs, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global highly potent active pharmaceutical ingredients market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global highly potent active pharmaceutical ingredients market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global highly potent active pharmaceutical ingredients (HPAPIs) market and included in this report are Alkermes plc, Cambrex Corporation, Dr. Reddy's Laboratories, Lonza Group, Novasep, Sandoz International GmbH, Pfizer, Inc., Sigma-Aldrich Co. LLC, and WuXi AppTec.To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.


News Article | November 2, 2016
Site: www.prnewswire.co.uk

RnRMarketResearch.com adds "Neutropenia - Pipeline Review, H2 2016" market research report to its store. The report provides an overview of the Neutropenia's therapeutic pipeline with comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. Complete report on H2 2016 pipeline review of Neutropenia with 31 market data tables and 14 figures, spread across 93 pages is available at http://www.rnrmarketresearch.com/neutropenia-pipeline-review-h2-2016-market-report.html. Neutropenia pipeline therapeutics constitutes close to 26 molecules. Out of which approximately 26 molecules are developed by Companies. The report outlays comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 3, 4, 9, 1 and 3 respectively. Furthermore, this report also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies discussed in this Neutropenia Pipeline Review, H2 2016 report include Apotex Inc., BeyondSpring Pharmaceuticals, Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Cleveland BioLabs, Inc., Coherus BioSciences, Inc., Dr. Reddy's Laboratories Limited, Eurofarma Laboratorios S.A., Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC, Richter Gedeon Nyrt., Sandoz International GmbH, Therapeutic Proteins International, LLC, Toko Pharmaceutical Industries Co., Ltd. and USV Pvt Ltd. Drug Profiles mentioned in this research report are ACN-8337, CBLB-612, EC-18, filgrastim, LG-7455, pegfilgrastim, pegfilgrastim (recombinant), plinabulin, romyelocel-L, ST-7 and tamibarotene. Scope of this report: The report provides a snapshot of the global therapeutic landscape of Neutropenia and reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Neutropenia therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Neutropenia. Another newly published market research report titled on Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Varicella Zoster (HHV-3) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Varicella Zoster (HHV-3) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Astellas Pharma Inc., Beijing Minhai Biotechnology Co., Ltd, Beijing Tiantan Biological Products Co., Ltd., ContraVir Pharmaceuticals, Inc., Epiphany Biosciences Inc., Foamix Pharmaceuticals Ltd., GeneOne Life Science, Inc., GlaxoSmithKline Plc, Green Cross Corporation, Merck & Co., Inc., N & N Pharmaceuticals Inc., NAL Pharmaceuticals Ltd., NanoViricides, Inc., ReceptoPharm, Inc., Sinovac Biotech Ltd., SK Chemicals Co., Ltd., TSRL, Inc., XBiotech Inc and Zydus Cadila Healthcare Limited. Varicella Zoster (HHV-3) Infections Pipeline market research report of 172 pages is available at http://www.rnrmarketresearch.com/varicella-zoster-hhv-3-infections-pipeline-review-h2-2016-market-report.html. RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.


News Article | December 2, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs has experienced robust market growth. Some of the factors which are triggering the market growth include growing incidences of diseases, rising demand for biosimilars drugs owing to their cost effectiveness and increasing demand to limit healthcare expenditures. However, stringent government regulations will affect biosimilars investments. Chronic & Autoimmune disorders segment is expected to grow at a highest CAGR during the forecast period owing to increasing incidences of autoimmune disorders. By geography, Europe dominated the global biosimilars market due to growing appearance of new market participants in this region. However, Asia Pacific is anticipated to grow at a highest CAGR during the forecast period due to rising funds towards the expansion of biosimilars market. Some of the key players in this market include are Mylan, Inc., Dr. Reddy's Laboratories, Amgen Inc., Sandoz International GmbH , Hospira, Inc., Merck KGAA, Celltrion, Inc., Biocon Ltd. , Teva Pharmaceutical Industries Ltd. and Roche Diagnostics. Products Covered: • Peptides • Erythropoietin • Interferon • Human Growth Hormone • Monoclonal Antibodies • Granulocyte Colony Stimulating Factor (G-CSF) • Insulin • Other Products Technology Covered: • Bioassay • Mass Spectrometry • Nuclear magnetic resonance (NMR) technology • Recombinant DNA Technology (rDNA technology) • Western Blotting • Electrophoresis • Chromatography • Monoclonal Antibodies (MAb) Technology Application Covered: • Growth Hormone Deficiency • Chronic and Autoimmune Diseases • Blood Disorders • Oncology Diseases • Other Applications Service Covered: • Clinical Trials • Contract Research and Manufacturing Services  Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


— Chronic Lymphocytic Leukemia (CLL) Pipeline Market Companies Involved in Therapeutics Development are 4SC AG, AbbVie Inc, Acetylon Pharmaceuticals Inc, Aeglea BioTherapeutics Inc, Altor BioScience Corp, Amgen Inc, Aprea AB, Aptevo Therapeutics Inc, Arno Therapeutics Inc, ArQule Inc, Astellas Pharma Inc, Astex Pharmaceuticals Inc, Baliopharm AG, Bayer AG, BeiGene Ltd, Bellicum Pharmaceuticals Inc, Biogen Inc, Bionomics Ltd, Bionovis SA, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, Cellectis SA, Cellular Biomedicine Group Inc, Coherus BioSciences Inc, CrystalGenomics Inc, Cyclacel Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GeneaMed Ltd, Genentech Inc, Genor BioPharma Co Ltd, Gilead Sciences Inc, Grupo Ferrer Internacional SA, Hutchison MediPharma Ltd, Hybrigenics SA, Igenica Biotherapeutics Inc, Immatics Biotechnologies GmbH, ImmunoGen Inc, Immunomedics Inc, Incyte Corp, Inflection Biosciences Ltd, Innate Pharma SA, Innovent Biologics Inc, Johnson & Johnson, Juno Therapeutics Inc, Kancera AB, Karyopharm Therapeutics Inc, Kite Pharma Inc, Les Laboratoires Servier SAS, LFB SA, Lymphocyte Activation Technologies SA, Medicenna Therapeutics Inc, MENTRIK Biotech LLC, Merck & Co Inc, Merck KGaA, Mesoblast Ltd, Millennium Pharmaceuticals Inc, MorphoSys AG, NantKwest Inc, Nordic Nanovector ASA, Novartis AG, Oncternal Therapeutics, Inc., Ono Pharmaceutical Co Ltd, Panacea Biotec Ltd, PEP-Therapy SAS, Pfizer Inc, Pharmacyclics Inc, PIQUR Therapeutics AG, Portola Pharmaceuticals Inc, Redx Pharma Plc, Respiratorius AB, Revitope Oncology, Inc., Rhizen Pharmaceuticals SA, Sandoz International GmbH, Sanofi, Selvita SA, Simcere Pharmaceutical Group, Sorrento Therapeutics Inc, Supratek Pharma Inc, Takeda Pharmaceutical Company Ltd, Targazyme Inc, TG Therapeutics Inc, The International Biotechnology Center (IBC) Generium, Theravectys SA, Tolero Pharmaceuticals Inc, TRACON Pharmaceuticals Inc, Tragara Pharmaceuticals Inc, Trillium Therapeutics Inc, United BioPharma, Inc., Unum Therapeutics Inc, Verastem Inc, VioQuest Pharmaceuticals Inc, Viralytics Ltd, Xencor Inc, ZIOPHARM Oncology Inc and Zymeworks Inc. This research provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774108 The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 5, 43, 45, 1, 3, 54, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 6, 8 and 7 molecules, respectively. Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research report at http://www.reportsnreports.com/purchase.aspx?name=774108 • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology). • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774108-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2016.html


— Follicular Lymphoma Pipeline Market Companies Involved in Therapeutics Development are AbbVie Inc, Affimed GmbH, Amgen Inc, Asana BioSciences LLC, Bayer AG, BeiGene Ltd, Bio-Path Holdings Inc, Biocon Ltd, Biogen Inc, Biogenomics Limited, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, Celldex Therapeutics Inc, Celltrion Inc, Cellular Biomedicine Group Inc, Coherus BioSciences Inc, Constellation Pharmaceuticals Inc, CSPC Pharmaceutical Group Limited, CTI BioPharma Corp, Curis Inc, Dynavax Technologies Corp, Eisai Co Ltd, EpiZyme Inc, F. Hoffmann-La Roche Ltd, Genentech Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Hutchison MediPharma Ltd, Immune Design Corp, ImmunoGen Inc, Immunomedics Inc, Johnson & Johnson, Juno Therapeutics Inc, Karyopharm Therapeutics Inc, Kite Pharma Inc, MedImmune LLC, Medivation Inc, MEI Pharma Inc, Merck & Co Inc, Merck KGaA, Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc, MorphoSys AG, Nordic Nanovector ASA, Novartis AG, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharmacyclics Inc, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Sandoz International GmbH, Seattle Genetics Inc, Takeda Pharmaceutical Company Ltd, TG Therapeutics Inc and Verastem Inc. Follicular lymphoma is a common type of non-Hodgkin Lymphoma (NHL). It is a slow-growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an "indolent" or "low-grade" lymphoma for its slow nature. Follicular lymphoma mainly affects older adults. Enlargement of lymph nodes is a common symptom. Fever, weight loss, sweating and fatigue are other symptoms of lymphoma. There are different types of treatment for patients with follicular lymphoma such as surgery, radiation therapy, and chemotherapy. This research provides comprehensive information on the therapeutics under development for Follicular Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774097 The Follicular Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 10, 46, 29, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 1 molecules, respectively. Follicular Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. • The pipeline guide provides a snapshot of the global therapeutic landscape of Follicular Lymphoma (Oncology). • The pipeline guide reviews pipeline therapeutics for Follicular Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Follicular Lymphoma (Oncology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Follicular Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Follicular Lymphoma (Oncology) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Follicular Lymphoma (Oncology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Follicular Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774097-follicular-lymphoma-pipeline-review-h2-2016.html


News Article | November 14, 2016
Site: www.newsmaker.com.au

WiseGuy Report’s latest Pharmaceutical and Healthcare disease pipeline guide Posterior Uveitis – Pipeline Review, H2 2016, provides an overview of the Posterior Uveitis (Ophthalmology) pipeline landscape. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. One of the types of uveitis is posterior uveitis. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication. WiseGuy Report’s Pharmaceutical and Healthcare latest pipeline guide Posterior Uveitis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Posterior Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Posterior Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Posterior Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 3 respectively. Posterior Uveitis. Posterior Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from WiseGuy Report’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. - The pipeline guide provides a snapshot of the global therapeutic landscape of Posterior Uveitis (Ophthalmology).  - The pipeline guide reviews pipeline therapeutics for Posterior Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.  - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.  - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.  - The pipeline guide reviews key companies involved in Posterior Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.  - The pipeline guide evaluates Posterior Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.  - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.  - The pipeline guide reviews latest news related to pipeline therapeutics for Posterior Uveitis (Ophthalmology) - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.  - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.  - Find and recognize significant and varied types of therapeutics under development for Posterior Uveitis (Ophthalmology).  - Classify potential new clients or partners in the target demographic.  - Develop tactical initiatives by understanding the focus areas of leading companies.  - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.  - Formulate corrective measures for pipeline projects by understanding Posterior Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.  - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.  - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. List of Tables  Number of Products under Development for Posterior Uveitis, H2 2016 7  Number of Products under Development by Companies, H2 2016 8  Comparative Analysis by Late Stage Development, H2 2016 9  Comparative Analysis by Clinical Stage Development, H2 2016 10  Comparative Analysis by Early Stage Development, H2 2016 11  Products under Development by Companies, H2 2016 12  Posterior Uveitis - Pipeline by Aciont Inc., H2 2016 13  Posterior Uveitis - Pipeline by Neuroptis Biotech, H2 2016 14  Posterior Uveitis - Pipeline by Oculis ehf, H2 2016 15  Posterior Uveitis - Pipeline by pSivida Corp., H2 2016 16  Posterior Uveitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 17  Posterior Uveitis - Pipeline by Sandoz International GmbH, H2 2016 18  Posterior Uveitis - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 19  Assessment by Monotherapy Products, H2 2016 20  Number of Products by Stage and Target, H2 2016 22  Number of Products by Stage and Mechanism of Action, H2 2016 24  Number of Products by Stage and Route of Administration, H2 2016 26  Number of Products by Stage and Molecule Type, H2 2016 28  Posterior Uveitis - Dormant Projects, H2 2016 52  Posterior Uveitis - Discontinued Products, H2 2016 53 For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


— The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum returns on investment. Biosimilars are seen as the key weapon to curbing soaring healthcare costs globally. The major factor that is driving the market for biosimilars industry is the fact that major biologics are nearing the patent cliff. Complete report on Biosimilars market spread across 177 pages providing 13 company profiles and 27 tables and 74 figures is now available at http://www.marketreportsonline.com/504244.html. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to curb healthcare costs globally, increasing nationwide government initiatives, and the strong pipeline for the biosimilar drugs is expected to fuel the biosimilars industry. On the other hand, high manufacturing complexities and costs, stringent regulatory requirements in countries and operational challenges are restricting the growth of the biosimilars market. Key Highlights of the Report Biosimilars Market - By Product Type • The erythropoietin (EPO) captures maximum share of the global biosmilars market. • The Granulocyte- Colony Stimulating Factor (G-CSF) market is expected to cross US$ 6 Billion mark by 2021. • The Human Growth Hormone (HGH) biosimilars market is expected to grow with a double digit CAGR during the period 2016 - 2021. • The monoclonal antibody is expected to show the highest growth rate during the period 2016 - 2021. • The insulin and interferon product segment each accounted for single digit share of the global biosimilars market respectively in 2015. Biosimilars Market - By Applications: 1. Among various application segments of biosimilar market, blood disorders and oncology together accounted for over 55% share of the global biosimilars market in 2015. 2. Growth hormone deficiencies application is expected to show double digit CAGR during the period 2016 - 2021. 3. The chronic and autoimmune disorders captured XX% share of the biosmilars market in 2015. Biosimilars Market - By Country Wise The market for biosimilars in the U.S. has gained momentum after the launch of Novartis’ Zarxio in September 2015. In the European countries, Germany is at the forefront with around XX% share of the biosimilars market in 2015 followed by France with XX% share in the same year. China accounted for XX% share of the global biosimilar market in 2015. India is seen as a key player in the biosimilar space with an exceptionally high number of approvals granted in the last decade compared to the global average. South Korea captured XX% of the global biosimilar market in 2015 being closely followed by Brazil with XX% share in the same year. Purchase a copy of this “Biosimilars Market” research report at USD 1350 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=504244. Global Biosimilars Company Analysis - 13 Companies Covered: Biocad, Celltrion Inc., Dong-A Socio Group, Pfizer Inc., Intas Pharmaceuticals Ltd., Sandoz International GmbH - A Novartis Company, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Amgen Inc., Biocon, Dr. Reddy’s Laboratories, Mylan & Merck KGaA This 177 Page report with 74 Figures and 27 Tables is analyzed from 6 viewpoints: 1. Global Biosimilars Market and Forecast - By Product Type 2. Global Biosimilars Market and Forecast - By Applications 3. Global Biosimilars Market and Forecast - By Country Wise 4. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis 5. Country with Biosimilar Guideline and Published Year 6. Global Biosimilars Market - Driving Factors and Challenges Global Biosimilars Market and Forecast - 5 Applications Covered: Oncology, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders & Other Applications Global Biosimilars Market and Forecast - 16 Countries Covered: United States, Canada, Argentina, Germany, France, Italy, Spain, United Kingdom, China, Japan, India, South Korea, Australia, Brazil, Mexico & Rest of the World Key Topics Covered in Global Biosimilars Market: 1. Executive Summary 2. Global Biosimilars Market and Forecast to 2021 3. Global Biosimilars Market Share and Forecast to 2021 4. Global Biosimilars Market and Forecast - By Product Type 5. Global Biosimilars Market and Forecast - By Applications 6. Global Biosimilars Market and Forecast - By Country Wise 7. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis 8. Biosimilars Approved in Europe 9. Country with Biosimilar Guideline and Published Year 10. Global Biosimilars Market - Driving Factors 11. Global Biosimilars Market – Challenges Explore more pharmaceuticals market research as well as other newly published reports by iGate Research at http://www.marketreportsonline.com/publisher/igate-research-market-research.html. For more information, please visit http://www.marketreportsonline.com/contacts/purchase.php?name=504244


News Article | November 15, 2016
Site: marketersmedia.com

— The report “Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020” analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW). The global biosimilars market is expected to reach $6.22 Billion by 2020 from $2.29 Billion in 2015, at a CAGR of 22.1% from 2015 to 2020. The report segments the market on the basis of product, application, and region. Among various product types, the recombinant nonglycosylated protein segment is expected to account for the largest share of the market in 2015. However, the recombinant glycosylated protein segment is expected to grow at the highest CAGR during the forecast period. A number of factors such as growing pressure to curtail healthcare expenditure, growing demand of biosimilar drugs due to their cost effectiveness, rising incidences of various diseases, increasing number of off-patented drugs, positive outcome in the ongoing clinical trials, and rising demand for biosimilars in different therapeutic applications such as rheumatoid arthritis and blood disorders are propelling the growth of the global market. On the other hand, high manufacturing complexities and costs, stringent regulatory requirements in countries, and innovative strategies by biologic drug manufacturers to restrict entry of new players are restricting the growth of the global market. Geographically, the global biosimilars market is dominated by Europe, followed by Asia-Pacific, Rest of the World (RoW), and North America. However, the Asia-Pacific region is likely to witness the highest growth rate during the forecast period. Factors such as developing healthcare infrastructure, presence of a large patient population, increasing funding/investments for the development of biosimilars, and growing focus of both international and domestic players on emerging Asia-Pacific countries are stimulating the growth of the market in this region. The key players in the global market include Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories (India), Biocon Limited (India), Mylan, Inc. (U.S.), Amgen (U.S.), Celltrion Inc. (South Korea), Roche Diagnostics (Switzerland), and Merck KGaA (Germany). For more information, please visit http://www.marketsandmarkets.com/pdfdownload.asp?id=40

Loading Sandoz International GmbH collaborators
Loading Sandoz International GmbH collaborators